Biolinerx Ltd. key statistics and ratios

In fiscal 2025, Biolinerx Ltd. had return on equity of -12.8%, an operating margin of -871.8%, debt equal to 0.0% of equity and a current ratio of 1.95. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biolinerx Ltd.: financial ratios, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	—	—	23.1%	68.0%	80.5%
Operating margin	—	—	<−999%	−70.5%	−871.8%
Net margin	—	—	<−999%	−31.9%	−171.7%
Free-cash-flow margin	—	—	−473.4%	−151.8%	−686.4%
Return on equity	−39.7%	−42.0%	−189.2%	−69.1%	−12.8%
Return on assets	−33.2%	−31.6%	−86.4%	−17.9%	−5.1%
Asset turnover	—	—	0.07	0.56	0.03
Current ratio	5.91	4.87	1.10	1.76	1.95
Debt to equity	—	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	—	—	260.8%	31.6%	685.8%
Capital spending as % of revenue	—	—	2.4%	0.2%	2.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · December 31, 2025

What it owns · $41m

Short-term assets $24mLonger-term assets $17m

What it owes, and who funded it · $36m

Short-term liabilities $12mLonger-term liabilities $5mShareholders' equity $18m

Short-term assets cover short-term liabilities $24m of assets due within a year against $12m of liabilities due within a year.
Short-term assets cover long-term liabilities $24m short-term assets against $5m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$10m against $1m of interest.

From Biolinerx Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BLRX vs LGVN BLRX vs DARE BLRX vs STTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biolinerx Ltd.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biolinerx Ltd.